Trial Profile
A pivotal trial of PLX-PAD in Japanese patients with critical limb ischemia
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Emiplacel (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Registrational; Therapeutic Use
- Sponsors Pluri
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 12 Aug 2016 New trial record
- 02 Aug 2016 According to a Pluristem Therapeutics media release, the company reached an agreement with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the protocol of this trial via Japan's accelerated regulatory pathway for regenerative medicine.